Brief: Kancera Provides Update On Development Of Its Pharmaceutical Project And Nominates New Drug Candidate

Novakand Pharma AB

21/04/2021 07:32

April 21 (Reuters) - Kancera AB  KANC.ST :
    * KANCERA PROVIDES AN UPDATE ON THE DEVELOPMENT OF THE
COMPANY'S
PHARMACEUTICAL PROJECT AND NOMINATES A NEW DRUG CANDIDATE
    * SUCCESSFUL SCALING UP OF PRODUCTION OF DRUG CANDIDATE
KAND145,
WHICH ENABLES PLANNED CLINICAL PREPARATORY STUDIES,
    * NEW DRUG CANDIDATE FOR RECTAL CANCER
    * NOMINATION OF KAND757 AS A DRUG CANDIDATE IN PFKFB3
PROJECT
AFTER POSITIVE EFFECTS ARE DOCUMENTED IN TUMOR PREPARATIONS FROM
PATIENTS WITH RECTAL CANCER.
    * TWO THIRDS OF PATIENTS HAVE NOW BEEN DOSED IN CLINICAL
STUDY OF
KAND567 FOR TREATMENT OF COVID-19; PATIENT RECRUITMENT IS
EXPECTED TO BE COMPLETED DURING CURRENT QUARTER
    * STUDY SHOWS  PFKFB3 INHIBITOR KAND757 KILLS TUMOR
PREPARATIONS
FROM RECTAL CANCER PATIENTS BY SELECTIVELY BLOCKING METABOLISM
    * A POTENTIAL DECISION TO TAKE KAND757 ON TO CLINICAL PHASE
IS
INTENDED TO BE MADE IN 2022 BASED ON RESULTS OF THESE STUDIES.

Source text for Eikon:  ID:nMFN5MXPT2 
Further company coverage:  KANC.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))